Compare National Beverage Corp. (FIZZ) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Globus Medical Inc. Class A Common Stock — how do they compare? National Beverage Corp. trades at $33.54 (market cap $3.08B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 3.3× National Beverage Corp.'s market cap, and National Beverage Corp. is more actively traded (604,078 versus 1,059,528). Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 32 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| FIZZ | GMED | |
|---|---|---|
Market Cap | $3.08B | $10.25B |
Volume | 604,078 | 1,059,528 |
Sector | Consumer Staples | Health |
52-Week High | $37.73 | $96.82 |
52-Week Low | $29.20 | $58.33 |
Typical Hold Time | 32 Days | 0 Days |
Enterprise Value | $3.04B | $9.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
National Beverage Corp. (FIZZ) trades at $33.54, up 4.32% with a bullish technical signal. The stock shows strong profitability with 14.81% net margins and 40.13% ROE, though recent quarters have seen earnings misses. Cash flow turned negative in 2025 due to significant financing outflows. Technical indicators suggest bullish momentum despite overbought RSI readings near 73.
FIZZ faces mixed sentiment with 50% analyst sell ratings but strong institutional interest. Revenue growth remains stagnant while margin pressure from input costs presents headwinds. The current valuation at 17.7x P/E appears reasonable given profitability, but execution risks and competitive pressures warrant caution for investors.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
